Dr. Supriya Mahajan
| Grant Category: | Fulbright-Nehru Senior Researcher |
| Field of Specialization: | HIV-1 pathogenesis – Immunology/Endocrinology |
| Name: | Dr. Supriya Mahajan |
| Official Address: | Department of Medicine, Division of Allergy/Immunology State University of New York Buffalo, New York |
| Indian Host Institution: | National
AIDS Research Institute Pune, Maharashtra |
| Duration of Grant & Start Date : | Duration: 4 months January 2012 |
| Brief Bio: | |
| Dr. Supriya Mahajan earned her Ph.D. from the All India Institute of Medical Sciences (AIIMS), New Delhi. She did her post doctoral training in metabolism from the Case Western Reserve University and in immunology at State University of New York. Dr. Mahajan has been working in the area of pathogenesis of HIV-1 particularly in the context of opiate abuse for almost a decade. She has described the molecular mechanisms underlying the role of drug abuse in the progression of HIV infections. Notably, she reported that a wide range of addictive drugs promoted susceptibility to and progression of HIV infections. She has received several scholarships and awards and is a active member of several professional societies and is also involved in the teaching and training programs in immunology at University at Buffalo. Dr. Mahajan's focus on innovation and translational research coupled with her strong work ethic has resulted in an excellent and extensive personal bibliography attesting to her scholarly productivity. She has authored 66 peer reviewed papers and is a invited reviewer for several scientific journals. The goal of Dr. Mahaajan's Fulbright-Nehru research is to establish collaborative research partnerships with premier academic institutions and Health center's that provide clinical care to AIDS patients. The project evaluates the genetic basis and metabolic consequences of HIV-1 associated lipodystrophy development and progression as a result of antiretroviral therapy in HIV-1 patients from two ethnically and viral strain distinct, patients cohorts (Clade B, C). Most importantly, the study will provide data to support advocacy for increased access to alternate safer 3rd and 4th generation ARV drugs in developing countries like India. She also aims to foster academic and social exchange between India and the United States. |
|
